A 26-year-old male patient was diagnosed with stage IIA cHL and received five-line treatment, including ABVD, GemOx-D, anti-PD-1/PD-L1 monoclonal antibodies, anti-CD47/PD-L1 bispecific antibodies, and BV combined with ICE, ultimately achieving first complete remission (CR). This evidence concerns the gene CD274 and classic Hodgkin lymphoma.